Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Children’s Oncology Group (COG) risk stratification.

• DOI: 10.1200/jco.2022.40.16_suppl.10013
• Publication Date: 2022-06-06T17:31:24Z
• Authors: Wendy B. London; Hannah Bender; Meredith Irwin; Michael D. Hogarty; Robert P. Castleb...; John M. Maris; Pei-Chi Kao; Arlene Naranjo; Susan Lerner Cohn
• Keywords: Cog

10013 Background: In 2006, COG reclassified subgroups of toddlers diagnosed with neuroblastoma from high-(HR) to intermediate-risk (IR), when the age cut-off for increased risk was raised 365 days (12 mo) 547 (18 (London, J Clin Onc 2005). The aim this retrospective study determine if excellent outcome maintained after a reduction therapy. Methods: Children < 3 yrs old at diagnosis, enrolled on biology 1990-2018, were eligible (n = 9,189). Therapy reduced two “cohorts interest” based change: 365-546 INSS stage 4, MYCN not amplified, favorable INPC, hyperdiploid tumors (12-18mo/Stage4/FavBiology); and, non-amplified and unfavorable INPC (12-18mo/Stage3/NotAmp/UnfavINPC). Log rank tests compared event-free (EFS) overall survival (OS) curves. Results: cohorts interest, patient (pt) characteristics similar ≤2006 vs > 2006. For 12-18mo/Stage4/FavBiology, 5-year EFS OS (± std error) before (≤2006; n 40) versus (> 2006; 55) in therapy similar: 89±5.1% 87±4.6% (p 0.7), 94±3.2% 0.4), respectively (Table). 12-18mo/Stage3/NotAmp/UnfavINPC, both 100%, 6) 4) combined 91±4.4% 88±4.3% 0.6), 91±4.5% 95±2.9% 0.5), respectively. Within HR pts ≤2006, EFS/OS 91±4.4%/91±4.5% (12-18mo/Stage4/FavBiology plus 12-18mo/Stage3/NotAmp/UnfavINPC) 38±1.3%/43±1.3% all other 0.0001; Table). IR 88±4.3%/95±2.9% 88±0.9%/95±0.6% 0.9). Conclusions: Our 19 year demonstrates that is among Stage4/FavBiology Stage3/Not Amp/Unfav significant high- treatment. Importantly, likely spared acute toxicity late effects known be associated Efforts identify additional pt who may require achieve long-term are critical improve health children neuroblastoma. [Table: see text]